Following an over 12% decline in the previous session in reaction to updates at the company’s R&D Day event, Moderna ...

Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.

Moderna Inc (NASDAQ:MRNA) unveiled key updates at its annual R&D Day by reducing annual R&D spending by $1.1 billion by 2027, ...

Moderna Inc.’s shares (NASDAQ:MRNA) sank 19% to a $64.11 low in early trading Sept. 12 as investors learned during the annual ...

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID ...

Moderna has vowed to cut annual R&D spending by $1.1 billion by 2027. The decision to shrink the budget by more than 20% follows commercial setbacks that have persuaded the biotech to take a “more ...

Drug maker Moderna, Inc. (MRNA), at its annual R&D Day event on Thursday, presented its outlook for fiscal 2025 and beyond, as well ...

Moderna 's ( MRNA -2.63%) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...

Moderna shares fell Thursday morning as the COVID vaccine maker said it plans to cut R&D spending by $1.1 billion over the next three years.

Researchers at multiple AViDD centers confirm that the NIH has offered a 1-year, no-cost extension, but it doesn’t come with ...

By investing heavily on EV R&D, India can further localise production to create more jobs, tap export markets to gain global ...

Stocks opened and closed in positive territory, though the path to the finish line was choppy. A mixed reading on wholesale ...